· Published by Health Canada · Official notice
This is a letter issued by the Therapeutic Products Directorate, Health Canada.
Notice about Health Canada advisories
February 12, 2002
To: Hospital Chief of Medical Staff, Otolaryngologists and Pharmacists in Retail Pharmacies
Please distribute to health professionals within your institution.
Health Canada, following a review of current national and international safety information and the scientific and medical literature, is advising health care professionals of important safety concerns related to injectable droperidol, a neuroleptic and antiemetic.
More than 60 reports of cases of QT prolongation, serious arrhythmia (e.g., torsades de pointes) and sudden death have been reported worldwide in patients receiving injectable droperidol. In Canada there have been 8 reports of cases with a fatal outcome in association with injectable droperidol and concomitant administration of anesthetics, anxiolytics, muscle relaxants and narcotic analgesics.
In order to minimize the cardiovascular risks associated with the use of injectable droperidol, the following measures are recommended:
You are referred to the Product Monograph for Droperidol Injection USP- 2.5 mg/mL (Sabex Inc. and Novopharm Limited) for information regarding indications and use of droperidol.
Janssen-Cilag Ltd issued a notice of discontinuation of their droperidol containing products worldwide on March 31/ 2001, following a risk-benefit assessment conducted by Janssen-Cilag. Although the focus of the safety issue identified by Janssen-Cilag Ltd was the risk of QT prolongation leading to Torsades de Pointes (TdP), and fatal ventricular arrhythmias with chronic use of the oral formulation of droperidol, these adverse events have also been reported with injectable droperidol use in several short-term indications including anaesthesia and nausea and vomiting following anesthesia. More than 60 reports of cardiovascular adverse reactions including QT prolongation, ventricular arrhythmia, and death have been reported worldwide with the use of injectable droperidol from Janssen-Cilag. In Canada, there are no oral droperidol formulations. However two injectable formulations are currently marketed by Sabex Inc. and Novopharm.
It should be noted that on December 05, 2001, the US FDA strengthened the warnings and precautions sections in the labeling for droperidol 2, and a Dear Doctor Letter was issued by Akorn Pharmaceuticals (manufacturer of droperidol in USA)Footnote 2.
Health Canada is assessing the situation and will continue to monitor the postmarketing safety data for droperidol to determine further action. Further information will be available upon completion of our assessment of injectable droperidol. All adverse drug reactions related to injectable droperidol in Canada should be reported to:
Any suspected adverse drug reactions can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Bureau of Licensed Product Assessment
Therapeutic Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD web site, along with the ADR Guidelines.
Yours sincerely,
original signed by
Robert G. Peterson, MD, PhD, MPH
Director General
Therapeutic Products Directorate
Sawyer CA, Baker AB, Ramzan I et al: Droperidol elimination after cardiopulmonary bypass surgery. J Clin Pharmacol 1998; 38:160-165.
FDA talk paper: FDA Strengthens Warnings for Droperidol and USA. Dear Health Professional Letter: Important Drug Warning. December 5/2001. http://www.fda.gov/medwatch/SAFETY/2001/safety01.htm#inapsi